Interpace Biosciences (IDXG) 10-Q 17 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 10, 2016
Document Information [Line Items]
Entity Registrant Name	Interpace Diagnostics Group, Inc.
Entity Central Index Key	1,054,102
Trading Symbol	idxg
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		18,162,671
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
ASSETS
Cash and cash equivalents	$ 1,693,000	$ 8,310,000
Short-term investments		106,000
Accounts receivable, net	2,753,000	2,806,000
Other current assets	2,087,000	2,569,000
Current assets from discontinued operations	150,000	5,374,000
Total current assets	6,683,000	19,165,000
Property and equipment, net	1,060,000	1,460,000
Other intangible assets, net	37,220,000	43,492,000
Other long-term assets	1,001,000	3,255,000
Long-term assets from discontinued operations		340,000
Total assets	45,964,000	67,712,000
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accounts payable	1,365,000	1,560,000
Accrued salary and bonus	3,089,000	2,424,000
Other accrued expenses	6,905,000	5,961,000
Current portion of long-term debt, net of debt discount	3,756,000	1,164,000
Current liabilities from discontinued operations	4,755,000	12,264,000
Total current liabilities	19,870,000	23,373,000
Contingent consideration	17,691,000	17,890,000
Long-term debt, net of debt discount	5,267,000	7,233,000
Other long-term liabilities	4,615,000	6,178,000
Total liabilities	47,443,000	54,674,000
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively	187,000	187,000
Additional paid-in capital	125,842,000	132,522,000
Accumulated deficit	(125,865,000)	(111,252,000)
Accumulated other comprehensive income		13,000
Treasury stock, at cost (542,543 and 1,042,543 shares, respectively)	(1,643,000)	(8,432,000)
Total stockholders' (deficit) equity	(1,479,000)	13,038,000
Total liabilities and stockholders' (deficit) equity	$ 45,964,000	$ 67,712,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Common Stock, Shares, Issued (in shares)	18,705,214	18,705,214
Common Stock, Shares, Outstanding (in shares)	18,162,671	17,662,671
Treasury Stock, Shares (in shares)	542,543	1,042,543

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue, net	$ 3,316	$ 2,506	$ 9,963	$ 6,876
Cost of revenue (excluding amortization of $970 and $986 for the three months and $2,909 and $2,825 for the nine months, respectively)	1,846	1,799	4,866	5,224
Gross profit	1,470	707	5,097	1,652
Operating expenses:
Sales and marketing	1,282	2,876	4,186	8,387
Research and development	659	1,000	1,339	1,646
General and administrative	2,858	2,498	7,655	8,909
Acquisition related amortization expense	970	986	2,909	2,825
Asset impairment	3,363		3,363
Change in fair value of contingent consideration	(1,174)		(1,174)
Total operating expenses	7,958	7,360	18,278	21,767
Operating loss	(6,488)	(6,653)	(13,181)	(20,115)
Interest expense	(539)	(884)	(1,601)	(2,616)
Other income (expense), net	4	(112)	14	(268)
Loss from continuing operations before tax	(7,023)	(7,649)	(14,768)	(22,999)
Provision (benefit) for income taxes	173	(180)	(54)	(430)
Loss from continuing operations	(7,196)	(7,469)	(14,714)	(22,569)
(Loss) income from discontinued operations, net of tax	(297)	2,574	101	6,828
Net loss	(7,493)	(4,895)	(14,613)	(15,741)
Net Loss and Comprehensive Loss	$ (7,493)	$ (4,895)	$ (14,613)	$ (15,741)
Basic and diluted (loss) income per share of common stock:
From continuing operations (in dollars per share)	$ (0.40)	$ (0.48)	$ (0.82)	$ (1.48)
From discontinued operations (in dollars per share)	(0.02)	0.16	0.01	0.45
Net loss per basic and diluted share of common stock (in dollars per share)	$ (0.41)	$ (0.31)	$ (0.81)	$ (1.03)
Weighted average number of common shares and common share equivalents outstanding:
Basic weighted average number of of common shares (in shares)	18,163	15,654	18,029	15,301
Diluted (in shares)	18,163	15,654	18,029	15,301

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Cost of Revenue, Amortization	$ 970	$ 986	$ 2,909	$ 2,825

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities
Net loss	$ (14,613,000)	$ (15,741,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,490,000	3,775,000
Realignment accrual accretion	29,000	104,000
Interest accretion	1,601,000	825,000
Provision for bad debt	482,000	202,000
Gain on sale of discontinued operations		(217,000)
Stock-based compensation	109,000	1,517,000
Asset impairment	3,363,000
Change in fair value of contingent consideration	(1,174,000)
Deferred taxes		(634,000)
Other (gains), losses and expenses, net	(4,000)
Other changes in assets and liabilities:
Decrease (increase) in accounts receivable	4,639,000	(4,257,000)
Decrease in unbilled receivable	16,000	702,000
Decrease in other current assets	1,272,000	1,084,000
Decrease in other long-term assets	754,000	2,137,000
(Decrease) increase in accounts payable	(761,000)	200,000
(Decrease) increase in unearned contract revenue	(11,000)	396,000
(Decrease) increase in accrued salaries and bonus	(685,000)	2,155,000
Decrease in accrued liabilities	(4,561,000)	(7,318,000)
(Decrease) increase in long-term liabilities	(563,000)	1,534,000
Net cash used in operating activities	(6,617,000)	(13,536,000)
Cash Flows From Investing Activities
Purchase of property and equipment		(583,000)
Net cash used in investing activities		(583,000)
Cash Flows From Financing Activities
Cash paid for repurchase of restricted shares		(37,000)
Net cash used in financing activities		(37,000)
Net increase (decrease) in cash and cash equivalents	(6,617,000)	(14,156,000)
Cash and cash equivalents – beginning	8,310,000	23,111,000
Cash and cash equivalents – ending	1,693,000	8,955,000
Cash paid for interest		$ 2,153,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. (the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016, as amended on April 29, 2016 and June 14, 2016. The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. All significant intercompany balances and transactions have been eliminated in consolidation. Discontinued operations include the Company's wholly owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (CSO) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three- and nine-month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

Note 2 - Liquidity and Manageme

Note 2 - Liquidity and Management's Plans	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. LIQUIDITY AND MANAGEMENT'S PLANS For the nine months ended September 30, 2016, the Company incurred a net loss of $14.6 million and cash used in operating activities was $6.6 million. The Company did not raise any capital or incur any funded debt during the first nine months of 2016, but it did enter into a Credit Agreement with SCM Specialty Finance Opportunities Fund, L.P. on September 28, 2016 as described further below, on which it has not yet drawn. The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations. The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2016, the Company had cash and cash equivalents of $1.7 million, net accounts receivable of $2.8 million, current assets of $6.7 million and current liabilities of $19.9 million. As a result of the sale of substantially all of its CSO business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on its molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company may require additional capital in 2016 and will require additional capital in 2017 and beyond. In order to obtain such capital and fund its operations, the Company may be required to restructure all or a portion of its obligations related to the sale of its CSO business as well as obligations owed to the former equity holders of RedPath Integrated Pathology, Inc.(“RedPath”) arising out of the Company’s acquisition of RedPath. The first payment of secured debt to RedPath Equityholder Representative, LLC (the “RedPath Equityholder Representative”), as representative of the former equity holders of RedPath, has been extended several times from its original due date of October 1, 2016 and is now due December 31, 2016 unless further extended. There is no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund the Company's operations for the rest of 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. Additionally, the Company continues to focus on increasing sales of its commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in obtaining capital and executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to sell off assets, seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. In the event of a default on its secured note, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. In such events, stockholders may not be able to recoup their investment. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. During the first nine months of 2016, the Company commenced negotiations with certain of its creditors and former sales representatives and executives to restructure its current and long-term obligations related to the sale of the majority of its CSO business in December 2015. The proposed restructuring by the Company includes reducing or extending the term of certain of its obligations, converting a portion to equity and/or forgiving portions thereof. However, any such restructuring may be dependent on the Company raising additional capital. The Company believes that this proposed restructuring, if achieved, will not only improve its liquidity but also provide the flexibility for future funding. No assurance, however, can be given that the negotiations to restructure the Company’s debt and obligations will be successful. At September 30, 2016, the Company had the following debt obligations that it has been seeking to restructure: 1. Future payments and conditions related to the $10.7 million secured note payable to the former equity holders of RedPath. 2. Severance obligations to former executives ($3.1 million, including taxes). 3. Obligations due to former sales representatives under the CSO incentive plan (up to $1 million including taxes). To date, 343 former sales representatives have accepted the Company’s offer to pay out approximately $0.6 million in equal installments over eight months. For the period ended September 30, 2016 approximately $0.1 million was paid out under this plan. 4. Various liabilities including trade payables, other employee severance in accrued expenses and certain liabilities from Discontinued Operations which are in the process of being renegotiated or restructured. There is, however, no guarantee that the Company will be successful in restructuring its outstanding debt. A summary of the Company’s most significant contractual obligations over the next 12 months are as follows: Total 0 to 3 months 3 to 6 months 6 to 12 months Note due Redpath Equityholders $ 4,001 $ 1,334 $ - $ 2,667 Severance obligations 3,137 3,137 - - DOJ settlement 665 85 85 495 Deferred Bonus - ERT salesforce 800 185 308 307 Total obligations $ 8,603 $ 4,741 $ 393 $ 3,469 On September 28, 2016 (the “Closing Date”), the Company and its wholly-owned direct and indirect subsidiaries, Interpace Diagnostics, LLC (“Interpace LLC”) and Interpace Diagnostics Corporation (“IDC” and together with Interpace LLC, its “Subsidiaries”), entered into a Credit Agreement (the “Credit Agreement”) with SCM Specialty Finance Opportunities Fund, L.P. (the “Lender”). Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide a revolving loan (the “Loan”) to the Company in the maximum principal amount of $1.2 million (“Facility Cap”). Also on the Closing Date, the Company and its Subsidiaries acknowledged and agreed to an Intercreditor Agreement (the “Intercreditor Agreement”) by and between the Lender and the RedPath Equityholder Representative pursuant to which the Lender has a first lien security interest on all of the accounts receivable (and related intangibles) of the Company and its Subsidiaries and the RedPath Equityholder Representative has a second lien security interest, subordinated to the Lender, on all the accounts receivables (and related intangibles) of the Company and its Subsidiaries. In addition, pursuant to the Intercreditor Agreement, the RedPath Equityholder Representative has a first lien security interest on all other assets of the Company and its Subsidiaries and the Lender has no lien with respect to such other assets. The maturity date of the Loan is September 28, 2018. The Loan bears interest at an annual rate equal to the Prime Rate (as defined in the Credit Agreement) plus 2.75%, payable in cash monthly in arrears. The interest rate will be increased by 5.0% in the event of a default under the Credit Agreement. Events of default under the Credit Agreement, some of which are subject to certain cure periods, include a failure to pay or perform obligations when due, the making of a material misrepresentation to the Lender, the rendering of certain judgments or decrees against the Company and its Subsidiaries and the initiation, voluntarily or involuntarily, of a bankruptcy or similar proceeding against the Company or its Subsidiaries. The Company agreed to pay certain out-of-pocket costs and expenses incurred by the Lender in connection with the Credit Agreement and related documents, the administration of the Loan and related documents and the enforcement or protection of the Lender’s rights. The Lender is also entitled to: (a) a $12,000 origination fee; (b) a monthly unused line fee equal to the amount which is one-twelfth of one percent (0.083%) of the difference between (i) the outstanding balance of the Loan during the preceding month, and (ii) the Facility Cap on the date of determination; (c) a monthly collateral management fee equal to one-sixth of one percent (0.1666%) of the average daily balance under the Credit Agreement outstanding during the preceding month; and (d) a termination fee equal to (i) two percent (2%) of the Facility Cap if the Credit Agreement is terminated before the first anniversary of the Closing Date (the “First Anniversary”), or (ii) one percent (1%) of the Facility Cap if the Credit Agreement is terminated after the First Anniversary. The Company must also pay certain fees in the event that (a) the amount outstanding under the Credit Agreement exceeds the availability under the Credit Agreement’s borrowing base, and (b) receivables are not properly deposited in the appropriate lockbox account. The Credit Agreement contains customary representations and warranties in favor of the Lender and certain covenants, including, among other things, financial covenants relating to loan turnover rates, liquidity and revenue targets. As of November 17, 2016, the Company had not borrowed any funds under the Credit Agreement. On September 30, 2016, the Company, Interpace LLC, and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fourth amendment to the note to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fifth amendment to the note to extend until December 31, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. In addition, the fifth amendment also amends the note to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week. The fifth amendment also contains a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016. Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first quarterly payment of principal under the note originally was due on October 1, 2016 and the first payment is now due on December 31, 2016. Subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or other equity or debt capital is not raised, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates. Reclassifications The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation. Receivables and Allowance for Doubtful Accounts The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors. The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016. Other Current Assets Other current assets consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 Indemnification assets $ 1,375 $ 875 Letters of credit - 360 Other receivables 666 1,048 Other 46 286 $ 2,087 $ 2,569 Other Intangible Assets, including Finite-Lived Intangible Assets The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets. Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen. Discontinued Operations The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Basic weighted average number of of common shares 18,163 15,654 18,029 15,301 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 18,163 15,654 18,029 15,301 The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Options - - - - Stock-settled stock appreciation rights (SARs) 1,027 1,028 1,027 1,028 Restricted stock and restricted stock units (RSUs) 1,151 1,745 1,151 1,745 Performance contingent SARs - 188 - 188 2,178 2,961 2,178 2,961

Note 4 - Other Intangible Asset

Note 4 - Other Intangible Assets	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. OTHER INTANGIBLE ASSETS The net carrying value of the identifiable intangible assets as of September 30, 2016 is as follows: As of September 30, 2016 As of December 31, 2015 Life Carrying Carrying (Years) Amount Amount Diagnostic assets: Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 Pancreas - - 2,882 Biobank - - 1,575 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett's test 9 18,351 18,351 Total $ 43,011 $ 47,468 Diagnostic lab: CLIA Lab 2.3 $ 609 $ 609 Accumulated Amortization $ (6,400 ) $ (4,585 ) Net Carrying Value $ 37,220 $ 43,492 Amortization expense was approximately $1.0 million for the three-month periods ended September 30, 2016 and 2015, respectively, and $2.9 million and $2.8 million for the nine-month periods ended September 30, 2016 and 2015, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches: 2016 2017 2018 2019 2020 $ 3,771 $ 4,272 $ 5,292 $ 5,292 $ 5,292 During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million resulting from a decline in the market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. FAIR VALUE MEASUREMENTS The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below: As of September 30, 2016 Fair Value Measurements Carrying Fair As of September 30, 2016 Amount Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Cash $ 1,693 $ 1,693 $ 1,693 $ - $ - Money market funds - - - - - $ 1,693 $ 1,693 $ 1,693 $ - $ - Marketable securities: U.S. Treasury securities $ - $ - $ - $ - $ - Liabilities: Contingent consideration: Asuragen $ 3,247 $ 3,247 $ - $ - $ 3,247 RedPath 14,653 14,653 - - 14,653 $ 17,900 $ 17,900 $ - $ - $ 17,900 As of December 31, 2015 Fair Value Measurements Carrying Fair As of December 31, 2015 Amount Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Cash $ 7,534 $ 7,534 $ 7,534 $ - $ - Money market funds 776 776 776 - - $ 8,310 $ 8,310 $ 8,310 $ - $ - Marketable securities: Money market funds $ 48 $ 48 $ 48 $ - $ - Mutual funds 58 58 58 - - U.S. Treasury securities 1,115 1,115 1,115 - - Government agency securities 131 131 131 - - $ 1,352 $ 1,352 $ 1,352 $ - $ - Liabilities: Contingent consideration: Asuragen $ 4,628 $ 4,628 $ - $ - $ 4,628 RedPath 13,921 13,921 - - 13,921 $ 18,549 $ 18,549 $ - $ - $ 18,549 The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of September 30, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3). In connection with the acquisition of certain assets from Asuragen and the acquisition of RedPath, the Company recorded contingent consideration related to contingent payments and other revenue based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. A rollforward of the carrying value of the contingent consideration from continuing operations from January 1, 2016 to September 30, 2016 is as follows: 2016 Adjustments January 1, Payments Accretion to Fair Value September 30, Asuragen $ 4,628 $ (450 ) $ 243 $ (1,174 ) $ 3,247 Redpath 13,921 - 732 - 14,653 $ 18,549 $ (450 ) $ 975 $ (1,174 ) $ 17,900 The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required. Certain of the Company's non-financial assets, such as other intangible assets and goodwill, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6 . COMMITMENTS AND CONTINGENCIES Letters of Credit As of September 30, 2016, the Company had $0.3 million in letters of credit outstanding as required by its existing facility leases. These letters of credit are collateralized by certain investments. In October 2016, the letters of credit were not renewed and the balance was distributed to our landlords who now hold the funds as security deposits on the Company’s facility leases. Contingency In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace LLC, entered into a Contingent Consideration Agreement with the RedPath Equityholder Representative. Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company’s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG® for the management of Barrett’s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen™ for predicting risk of progression from Barrett’s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its CSO business in December 2015, decreasing the balance in treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million. Litigation Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity. The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of September 30, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements. In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million. Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for $2.5 million of the obligation and has recorded an indemnification asset of that amount within other non-current assets. In May 2016 the Company renegotiated payment terms with the DOJ related to a $250,000 payment associated with performance in fiscal 2014 that resulted in an agreement that the Company pay $85,000 on July 31, 2016, $85,000 on October 31, 2016 and $80,000 on February 28, 2017. Accordingly, $170,000 was paid to the DOJ in 2016. During the nine months ended September 30, 2016, the Company has $1.7 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.7 million is included in other accrued expenses other long-term liabilities Prolias Technologies, Inc. v. PDI, Inc. On April 8, 2015, Prolias Technologies, Inc.(“Prolias”) filed a complaint (the “Complaint”) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. (Docket No. MRS-L-899-15). In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto (collectively, the “Agreement”) whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as "Thymira." Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer. Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit. On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied that it had any liability to Prolias for the claims raised in the Complaint. In the Counterclaim, the Company sought (a) to recover from Polias the principal amount of $500,000 plus interest that was due and owing under a March 18, 2014 promissory note that Prolias delivered to the Company and (b) to compel Prolias to execute and deliver a $1 million promissory note to memorialize Prolias’s repayment obligations of money the Company advanced under the Agreement. The parties exchanged documents in the fourth quarter of 2015. On December 18, 2015, Prolias moved for temporary restraints as to an asset sale of the Company. The Court denied the temporary restraints on December 21, 2015 and, when Prolias pursued the restraints in the form of a preliminary injunction motion, the Court denied that as well on February 4, 2016. Prolias’s separate motion to disqualify the Company’s counsel was also denied by the Court on February 4, 2016. On February 24, 2016, Prolias moved for leave to appeal the interlocutory order denying the disqualification of Company’s counsel. On May 11, 2016, the Appellate Division granted the motion for leave to appeal and then summarily affirmed the denial of Prolias’s motion to disqualify the Company’s counsel. On March 29, 2016, Prolias’ counsel moved to withdraw from representing Prolias. On April 7, 2016, the Company conditionally opposed the motion to withdraw pending prompt appointment of new counsel for Prolias. On April 19, 2016, the Court denied the motion without prejudice. On April 26, 2016, Prolias’ counsel renewed its motion to withdraw. On May 27, 2016, the Court granted the motion to withdraw and ordered Prolias to retain substitute counsel within 30 days. On July 6, 2016, the Company moved to dismiss Prolias’ complaint and strike Prolias’ answer to the Company’s counterclaims for failure to retain substitute counsel within 30 days as required by the Court’s May 27th Order. On August 15, 2016, the Court granted the Company’s motion and dismissed Prolias’ complaint with prejudice and struck Prolias’ answer to the Company’s counterclaims. On September 22, 2016, the Court granted the Company’s request to enter default against Prolias for failure to plead or otherwise respond to the counterclaims. Thereafter, on October 13, 2016, the Company filed an application to enter final judgment and taxing of costs against Prolias. The Company requested that the Court enter final judgment against Prolias and for the Company in the amount of $621,236.16, plus ten percent interest continuing to accrue on the principal balance of $500,000.00 unless and until paid, attorneys’ fees and costs of $390,769.04, and a declaratory judgment that Prolias is deemed to have executed and delivered to the Company a promissory note in the amount of $1,000,000 under Article 10.2(a) of the Collaboration Agreement. The Company is awaiting a response from the Court on the application for entry of final judgment. Swann v. Akorn, Inc., and Interpace Diagnostics Group, Inc. On May 27, 2016, Michael J. Swann, one of the Company’s former employees, filed a complaint against the Company in the Court of Common Pleas of the Fifth Judicial Circuit in South Carolina in a matter entitled Michael J. Swann v. Akorn, Inc., and Interpace Diagnostic Group Inc. (Civil Action No. 2016-CP-40-03362). In the complaint, Mr. Swann alleges, among other things, that he was discriminated against and wrongfully terminated as a member of a sales force marketing pharmaceutical products of Akorn, Inc., because of an illness suffered by Mr. Swann. Mr. Swann alleges that he was discriminated against in violation of the Americans with Disabilities Act/Americans with Disabilities Act Amendments Act and the Family Medical Leave Act and seeks damages for back pay, reinstatement, front pay, compensatory and punitive damages in an amount not less than $300,000, attorney’s fees and costs. The Company denies that it is liable to Mr. Swann for any of the claims asserted and intends to vigorously defend itself against those claims. Severance In 2015, in connection with the sale of the majority of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to approximately $3.7 million. During the first quarter ended March 31, 2016 the Company recorded additional severance obligations as it continued to right-size the organization and wind down its CSO business. The Company recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations. The current severance liability as of September 30, 2016 is $3.1 million, of which $2.3 million resides in continuing operations and $0.8 million is in discontinued operations.

Note 7 - Accrued Expenses and L

Note 7 - Accrued Expenses and Long-term Liabilities	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	7. ACCRUED EXPENSES AND LONG-TERM LIABILITIES Other accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 Accrued royalties $ 504 $ 111 Self insurance and benefit accruals 272 366 Indemnification liability 875 875 Contingent consideration 209 659 Rent payable 78 127 DOJ settlement 665 250 Accrued professional fees 1,320 775 Taxes payable 691 591 Unclaimed property 544 546 Directors fees and insurance 208 107 All others 1,539 1,554 $ 6,905 $ 5,961 Long-term liabilities consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 Rent payable $ - $ 52 Uncertain tax positions 3,556 3,425 DOJ settlement (indemnified by RedPath) 1,000 2,500 Other 59 201 $ 4,615 $ 6,178

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8 . STOCK-BASED COMPENSATION Stock Incentive Plan In 2015, the board of directors (the Board) and stockholders approved the Company’s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company’s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan, which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan. The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan. Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee. Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for delivery under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units (RSU’s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. In February 2016, certain employees and members of the Company’s Board were granted approximately 1.3 million RSU’s at a weighted average grant price of $0.25. These shares vest one-third each year on the anniversary of the date of grant. The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the nine month periods ended September 30, 2016 and September 30, 2015: Nine Months Ended September 30, 2016 2015 Risk-free interest rate - 1.02 % Expected life (years) - 3.5 Expected volatility - 54.47 % Dividend yield - - The Company recognized approximately $0.02 million and $0.3 million of stock-based compensation expense during each of the three month periods ended September 30, 2016 and 2015, respectively, and $0.1 million and $1.0 million during each of the nine month periods ended September 30, 2016 and 2015, respectively. On October 14, 2016, the Company’s Chief Executive Officer, Chief Financial Officer and certain employees were granted incentive stock options to purchase an aggregate of 878,744 shares of common stock with an exercise price of $0.16 per share and, subject generally to the executive’s or employee’s, as applicable, continued service with the Company, vest in equally monthly installments over a period of one year.

Note 9 - Income Taxes

Note 9 - Income Taxes	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. INCOME TAXES Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2016 and 2015: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Provision (benefit) from income tax $ 173 $ (180 ) $ (54 ) $ (430 ) Effective income tax rate (2.5% ) 2.4 % 0.4 % 1.9 % Income tax expense and benefit for the three- and nine-month periods ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification . Income tax benefit for the three- and nine-month periods ended September 30, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.

Note 10 - Segment Information

Note 10 - Segment Information	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	10. SEGMENT INFORMATION Effective December 31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its CSO business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company. The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.

Note 11 - Discontinued Operatio

Note 11 - Discontinued Operations	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	11. DISCONTINUED OPERATIONS The table below presents the significant components of CSO, Group DCA's, Pharmakon's and TVG’s results included in (Loss) Income from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the three- and nine-months ended September 30, 2016 and 2015. Three Months Ending September 30, Nine Months Ending September 30, 2016 2015 2016 2015 Revenue, net $ - $ 34,119 $ 1,644 $ 104,408 (Loss) income from discontinued operations (414 ) 2,576 (1,006 ) 6,615 Gain on sale of assets - - 1,326 217 (Loss) income from discontinued operations, before tax (414 ) 2,576 320 6,832 Income tax (benefit) expense (117 ) 2 219 4 (Loss) income from discontinued operations, net of tax $ (297 ) $ 2,574 $ 101 $ 6,828 The assets and liabilities classified as discontinued operations relate to CSO, Group DCA, Pharmakon, and TVG. As of September 30, 2016 and December 31, 2015, these assets and liabilities are in the accompanying balance sheets as follows: For the Nine Months Ended September 30, 2016 For the Year Ended December 31, 2015 CSO DCA/TVG Total CSO DCA/TVG Total Accounts receivable, net $ - $ - $ - $ 3,296 $ - $ 3,296 Unbilled receivable, net - - - 16 - 16 Other - 150 150 2,062 - 2,062 Current assets from discontinued operations - 150 150 5,374 - 5,374 Property and equipment, net - - - 190 - 190 Other - - - - 150 150 Long-term assets from discontinued operations - - - 190 150 340 Total assets $ - $ 150 $ 150 $ 5,564 $ 150 $ 5,714 Accounts payable $ 947 $ - $ 947 $ 3,767 $ - $ 3,767 Unearned contract revenue - - - 11 - 11 Accrued salary and bonus 1,686 - 1,686 3,036 - 3,036 Other 2,052 70 2,122 5,092 358 5,450 Current liabilities from discontinued operations 4,685 70 4,755 11,906 358 12,264 Total liabilities $ 4,685 $ 70 $ 4,755 $ 11,906 $ 358 $ 12,264

Note 12 - Long-term Debt

Note 12 - Long-term Debt	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Long-term Debt [Text Block]	12. LONG-TERM DEBT On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the RedPath Equityholder Representative, on behalf of the former equity holders of RedPath, dated October 31, 2014 (the Note). The Note is $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October 1, 2016. On September 30, the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to November 1, 2016. Effective October 31, 2016, the Company and the RedPath Equityholder Representative amended the Note to further extend the due date of the first installment to November 20, 2016. On November 16, 2016 the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to December 31, 2016, to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week and to add a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016. Subsequent payments on the Note are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In December 2015, pursuant to the sale of substantially all of the CSO business, the Note was amended so that the CSO sales proceeds would not have to be applied against the Note payable balance. The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries pursuant to a Guarantee and Collateral Agreement (the “Subordinated Guarantee”) in favor of the RedPath Equityholder Representative. Pursuant to the Subordinated Guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the RedPath Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended September 30, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. During the nine months ended September 30, 2016 and 2015, the Company accreted approximately $0.6 million into interest expense, respectively, for each period. As of September 30, 2016, the balance of the Note is approximately $9.0 million and the unamortized discount is $1.7 million. Principal payments due related to the long-term debt, subsequent to the amendment to the Note that was entered into on November 16, 2016, over the next three years are as follows: 2016 2017 2018 Note $ 1,334 $ 4,001 $ 5,335 The Company currently has an indemnification asset of $1.5 million relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. The related DOJ liability is $1.7 million and as the Company makes payments to the DOJ, it may reduce the balance owed on the Note by the same amount. In addition, the Company entered into the Credit Agreement with SWK Funding LLC (the Agent) and the lenders party thereto in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the Loan was October 31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement. Upon the sale of substantially all of the CSO business on December 22, 2015, the Company used a portion of the net proceeds from the transaction to pay the balance of the outstanding loan in the aggregate principal amount of $20.0 million, and an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.

Note 13 - Supplemental Cash Flo

Note 13 - Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	13. SUPPLEMENTAL CASH FLOW INFORMATION The following table represents cash flows (used in) provided by the Company's discontinued operations for the nine months ended September 30, 2016 and 2015: Nine Months Ended September 30, 2016 2015 Net cash (used in) provided by operating activities of discontinued operations $ (1,486 ) $ 7,466 Net cash (used in) provided by investing activities of discontinued operations $ - $ -

Note 14 - Recent Accounting Pro

Note 14 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	14. RECENT ACCOUNTING PRONOUNCEMENTS In August 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its consolidated financial position, results of operations and related disclosures. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which when effective will require organizations that lease assets (e.g., through "leases") to recognize assets and liabilities for the rights and obligations created by the leases on the balance sheet. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help investors and financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position and results of operations. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contract with Customers - Narrow-Scope Improvements and Practical Expedients". In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing". In March 2016, the FASB issued ASU 2016-08, "Revenue from Contract with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)". In August 2015, the FASB issued ASU 2015-14 deferring the effective date to annual and interim periods. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers". The core principle of these ASUs are that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 affect only the narrow aspects of the guidance, such as assessing the collectability criterion and accounting for contracts that do not meet the criterion, presentation of sales and other similar taxes collected from customers, non-cash consideration, and contract modifications at transition. ASU 2016-10 clarifies two aspects of the guidance: identifying performance obligations and the licensing implementation. The intention of ASU 2016-08 is to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2015-14 defers the effective date to annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted, but not earlier than the original effective date of annual and interim periods beginning on or after December 15, 2016, for public entities. ASU 2014-09 is a comprehensive new revenue recognition model for revenue from contract with customers. The Company will adopt these ASUs when effective.

Note 15 - Other Subsequent Even

Note 15 - Other Subsequent Events	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	15. OTHER SUBSEQUENT EVENTS On October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of the Board effective as of September 30, 2016. In connection with Dr. Dreismann’s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, the Company notified NASDAQ that, as a result of the vacancy on the Audit Committee of the Board (the “Audit Committee”) created by Dr. Dreismann’s resignation, the Audit Committee only has two members and the Company is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee be comprised of at least three members. In response to the Company’s notice, NASDAQ issued a letter to the Company on October 6, 2016 acknowledging the Company’s notice that it is no longer in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A). In its letter, NASDAQ notified the Company that it can rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4), which allows the Company until the earlier of (i) its next annual meeting of stockholders or (ii) October 2, 2017 to regain compliance, or, if the next annual meeting of stockholders is held before March 29, 2017, then the Company must evidence compliance no later than March 29, 2017. The Company intends to appoint an additional independent director to the Board and to the Audit Committee prior to the end of the cure period.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Receivables and Allowance for Doubtful Accounts The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors. The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.
Other Current Assets, Policy [Policy Text Block]	Other Current Assets Other current assets consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 Indemnification assets $ 1,375 $ 875 Letters of credit - 360 Other receivables 666 1,048 Other 46 286 $ 2,087 $ 2,569
Goodwill and Intangible Assets, Policy [Policy Text Block]	Other Intangible Assets, including Finite-Lived Intangible Assets The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets. Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Basic weighted average number of of common shares 18,163 15,654 18,029 15,301 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 18,163 15,654 18,029 15,301 The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Options - - - - Stock-settled stock appreciation rights (SARs) 1,027 1,028 1,027 1,028 Restricted stock and restricted stock units (RSUs) 1,151 1,745 1,151 1,745 Performance contingent SARs - 188 - 188 2,178 2,961 2,178 2,961

Note 2 - Liquidity and Manage23

Note 2 - Liquidity and Management's Plans (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	Total 0 to 3 months 3 to 6 months 6 to 12 months Note due Redpath Equityholders $ 4,001 $ 1,334 $ - $ 2,667 Severance obligations 3,137 3,137 - - DOJ settlement 665 85 85 495 Deferred Bonus - ERT salesforce 800 185 308 307 Total obligations $ 8,603 $ 4,741 $ 393 $ 3,469

Note 3 - Summary of Significa24

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Other Assets [Table Text Block]	September 30, 2016 December 31, 2015 Indemnification assets $ 1,375 $ 875 Letters of credit - 360 Other receivables 666 1,048 Other 46 286 $ 2,087 $ 2,569
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Basic weighted average number of of common shares 18,163 15,654 18,029 15,301 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 18,163 15,654 18,029 15,301
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Options - - - - Stock-settled stock appreciation rights (SARs) 1,027 1,028 1,027 1,028 Restricted stock and restricted stock units (RSUs) 1,151 1,745 1,151 1,745 Performance contingent SARs - 188 - 188 2,178 2,961 2,178 2,961

Note 4 - Other Intangible Ass25

Note 4 - Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	As of September 30, 2016 As of December 31, 2015 Life Carrying Carrying (Years) Amount Amount Diagnostic assets: Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 Pancreas - - 2,882 Biobank - - 1,575 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett's test 9 18,351 18,351 Total $ 43,011 $ 47,468 Diagnostic lab: CLIA Lab 2.3 $ 609 $ 609 Accumulated Amortization $ (6,400 ) $ (4,585 ) Net Carrying Value $ 37,220 $ 43,492
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2016 2017 2018 2019 2020 $ 3,771 $ 4,272 $ 5,292 $ 5,292 $ 5,292

Note 5 - Fair Value Measureme26

Note 5 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	As of September 30, 2016 Fair Value Measurements Carrying Fair As of September 30, 2016 Amount Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Cash $ 1,693 $ 1,693 $ 1,693 $ - $ - Money market funds - - - - - $ 1,693 $ 1,693 $ 1,693 $ - $ - Marketable securities: U.S. Treasury securities $ - $ - $ - $ - $ - Liabilities: Contingent consideration: Asuragen $ 3,247 $ 3,247 $ - $ - $ 3,247 RedPath 14,653 14,653 - - 14,653 $ 17,900 $ 17,900 $ - $ - $ 17,900 As of December 31, 2015 Fair Value Measurements Carrying Fair As of December 31, 2015 Amount Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Cash $ 7,534 $ 7,534 $ 7,534 $ - $ - Money market funds 776 776 776 - - $ 8,310 $ 8,310 $ 8,310 $ - $ - Marketable securities: Money market funds $ 48 $ 48 $ 48 $ - $ - Mutual funds 58 58 58 - - U.S. Treasury securities 1,115 1,115 1,115 - - Government agency securities 131 131 131 - - $ 1,352 $ 1,352 $ 1,352 $ - $ - Liabilities: Contingent consideration: Asuragen $ 4,628 $ 4,628 $ - $ - $ 4,628 RedPath 13,921 13,921 - - 13,921 $ 18,549 $ 18,549 $ - $ - $ 18,549
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2016 Adjustments January 1, Payments Accretion to Fair Value September 30, Asuragen $ 4,628 $ (450 ) $ 243 $ (1,174 ) $ 3,247 Redpath 13,921 - 732 - 14,653 $ 18,549 $ (450 ) $ 975 $ (1,174 ) $ 17,900

Note 7 - Accrued Expenses and27

Note 7 - Accrued Expenses and Long-term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2016 December 31, 2015 Accrued royalties $ 504 $ 111 Self insurance and benefit accruals 272 366 Indemnification liability 875 875 Contingent consideration 209 659 Rent payable 78 127 DOJ settlement 665 250 Accrued professional fees 1,320 775 Taxes payable 691 591 Unclaimed property 544 546 Directors fees and insurance 208 107 All others 1,539 1,554 $ 6,905 $ 5,961
Schedule of Other Assets and Other Liabilities [Table Text Block]	September 30, 2016 December 31, 2015 Rent payable $ - $ 52 Uncertain tax positions 3,556 3,425 DOJ settlement (indemnified by RedPath) 1,000 2,500 Other 59 201 $ 4,615 $ 6,178

Note 8 - Stock-based Compensa28

Note 8 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2016 2015 Risk-free interest rate - 1.02 % Expected life (years) - 3.5 Expected volatility - 54.47 % Dividend yield - -

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Provision (benefit) from income tax $ 173 $ (180 ) $ (54 ) $ (430 ) Effective income tax rate (2.5% ) 2.4 % 0.4 % 1.9 %

Note 11 - Discontinued Operat30

Note 11 - Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Components of Loss from Discontinued Operations [Table Text Block]	Three Months Ending September 30, Nine Months Ending September 30, 2016 2015 2016 2015 Revenue, net $ - $ 34,119 $ 1,644 $ 104,408 (Loss) income from discontinued operations (414 ) 2,576 (1,006 ) 6,615 Gain on sale of assets - - 1,326 217 (Loss) income from discontinued operations, before tax (414 ) 2,576 320 6,832 Income tax (benefit) expense (117 ) 2 219 4 (Loss) income from discontinued operations, net of tax $ (297 ) $ 2,574 $ 101 $ 6,828
Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]	For the Nine Months Ended September 30, 2016 For the Year Ended December 31, 2015 CSO DCA/TVG Total CSO DCA/TVG Total Accounts receivable, net $ - $ - $ - $ 3,296 $ - $ 3,296 Unbilled receivable, net - - - 16 - 16 Other - 150 150 2,062 - 2,062 Current assets from discontinued operations - 150 150 5,374 - 5,374 Property and equipment, net - - - 190 - 190 Other - - - - 150 150 Long-term assets from discontinued operations - - - 190 150 340 Total assets $ - $ 150 $ 150 $ 5,564 $ 150 $ 5,714 Accounts payable $ 947 $ - $ 947 $ 3,767 $ - $ 3,767 Unearned contract revenue - - - 11 - 11 Accrued salary and bonus 1,686 - 1,686 3,036 - 3,036 Other 2,052 70 2,122 5,092 358 5,450 Current liabilities from discontinued operations 4,685 70 4,755 11,906 358 12,264 Total liabilities $ 4,685 $ 70 $ 4,755 $ 11,906 $ 358 $ 12,264

Note 12 - Long-term Debt (Table

Note 12 - Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Debt [Table Text Block]	2016 2017 2018 Note $ 1,334 $ 4,001 $ 5,335

Note 13 - Supplemental Cash F32

Note 13 - Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended September 30, 2016 2015 Net cash (used in) provided by operating activities of discontinued operations $ (1,486 ) $ 7,466 Net cash (used in) provided by investing activities of discontinued operations $ - $ -

Note 2 - Liquidity and Manage33

Note 2 - Liquidity and Management's Plans (Details Textual)	Sep. 30, 2016USD ($)	Sep. 28, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Nov. 14, 2016USD ($)	Dec. 31, 2014USD ($)
CSO [Member]
Proceeds from Divestiture of Businesses			$ 26,800,000
Secured Note Payable to RedPath Equity Representative [Member]
Contractual Obligation	$ 10,700,000			$ 10,700,000		$ 10,700,000
Debt Instrument, Covenant Term, Net Cash Balance, Amount	400,000
Debt Instrument, Periodic Payment, Principal	$ 1,333,750
Debt Instrument, Number of Periodic Payments, Principal	8			8		8
Employee Severance [Member]
Contractual Obligation	$ 3,100,000			$ 3,100,000		$ 3,100,000
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member] | Maximum [Member]
Contractual Obligation	1,000,000			1,000,000		1,000,000
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member]
Contractual Obligation	$ 600,000			$ 600,000		$ 600,000
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member]
Long-term Line of Credit								$ 0
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,200,000
Debt Instrument, Interest Rate, Increase in Event of Default		5.00%
Debt Instrument, Fee Amount		$ 12,000
Debt Instrument, Percentage Used to Determine Monthly Unused Line Fee		0.083%
Debt Instrument, Percentage Used to Determine Monthly Collateral Management Fee		0.1666%
Debt Instrument, Percentage Used to Determine Termination Fee, Before First Anniversary		2.00%
Debt Instrument, Percentage Used to Determine Termination Fee, After First Anniversary		1.00%
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member]
Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date	343			343		343
Payments for Restructuring						$ 100,000
Net Income (Loss) Attributable to Parent				$ (7,493,000)	$ (4,895,000)	(14,613,000)	$ (15,741,000)
Net Cash Provided by (Used in) Operating Activities						(6,617,000)	(13,536,000)
Cash and Cash Equivalents, at Carrying Value	$ 1,693,000		8,310,000	1,693,000	$ 8,955,000	1,693,000	$ 8,955,000		$ 23,111,000
Accounts Receivable, Net, Current	2,753,000		2,806,000	2,753,000		2,753,000
Assets, Current	6,683,000		19,165,000	6,683,000		6,683,000
Liabilities, Current	$ 19,870,000		23,373,000	$ 19,870,000		$ 19,870,000
Repayments of Long-term Debt			$ 21,600,000

Note 2 - Liquidity and Manage34

Note 2 - Liquidity and Management's Plan - Contractual Obligations Due in the Next 12 Months (Details) $ in Thousands	Sep. 30, 2016USD ($)
Secured Note Payable to RedPath Equity Representative [Member]
Contractual Obligations, Due	$ 4,001
Contractual Obligations, Due in 0 to 3 Months	1,334
Contractual Obligations, Due in 3 to 6 Months
Contractual Obligations, Due in 6 to 12 Months	2,667
DOJ Settlement [Member]
Contractual Obligations, Due	665
Contractual Obligations, Due in 0 to 3 Months	85
Contractual Obligations, Due in 3 to 6 Months	85
Contractual Obligations, Due in 6 to 12 Months	495
Employee Severance [Member]
Contractual Obligations, Due	3,137
Contractual Obligations, Due in 0 to 3 Months	3,137
Contractual Obligations, Due in 3 to 6 Months
Contractual Obligations, Due in 6 to 12 Months
Interpace Diagnostics, LLC [Member]
Contractual Obligations, Due	800
Contractual Obligations, Due in 0 to 3 Months	185
Contractual Obligations, Due in 3 to 6 Months	308
Contractual Obligations, Due in 6 to 12 Months	307
Contractual Obligations, Due	8,603
Contractual Obligations, Due in 0 to 3 Months	4,741
Contractual Obligations, Due in 3 to 6 Months	393
Contractual Obligations, Due in 6 to 12 Months	$ 3,469

Note 3 - Summary of Significa35

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			9 years
Allowance for Doubtful Accounts Receivable, Current	$ 1,300		$ 1,300
Asset Impairment Charges	$ 3,363		$ 3,363

Note 3 - Summary of Significa36

Note 3 - Summary of Significant Accounting Policies - Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Indemnification assets	$ 1,375	$ 875
Letters of credit		360
Other receivables	666	1,048
Other	46	286
	$ 2,087	$ 2,569

Note 3 - Summary of Significa37

Note 3 - Summary of Significant Accounting Policies - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Basic weighted average number of of common shares (in shares)	18,163	15,654	18,029	15,301
Potential dilutive effect of stock-based awards (in shares)
Diluted weighted average number of common shares (in shares)	18,163	15,654	18,029	15,301

Note 3 - Summary of Significa38

Note 3 - Summary of Significant Accounting Policies - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)
Stock Appreciation Rights (SARs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,027	1,028	1,027	1,028
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,151	1,745	1,151	1,745
Performance Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		188		188
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	2,178	2,961	2,178	2,961

Note 4 - Other Intangible Ass39

Note 4 - Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Amortization of Intangible Assets	$ 970	$ 986	$ 2,909	$ 2,825
Asset Impairment Charges	$ 3,363		$ 3,363

Note 4 - Other Intangible Ass40

Note 4 - Other Intangible Assets - Identifiable Intangible Assets Carrying Value (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Diagnostic Test, Thyroid [Member] | Asuragen [Member]
Finite-lived intangible asset, useful life	9 years
Finite-Lived Intangible Assets, Net	$ 8,519	$ 8,519
Diagnostic Test, Pancreas [Member] | Asuragen [Member]
Finite-lived intangible asset, useful life
Finite-Lived Intangible Assets, Net		2,882
Diagnostic Test, Pancreas [Member] | RedPath [Member]
Finite-lived intangible asset, useful life	7 years
Finite-Lived Intangible Assets, Net	$ 16,141	16,141
Diagnostic Test, Biobank [Member] | Asuragen [Member]
Finite-lived intangible asset, useful life
Finite-Lived Intangible Assets, Net		1,575
Diagnostic Test, Barrett's RedPath [Member] | RedPath [Member]
Finite-lived intangible asset, useful life	9 years
Finite-Lived Intangible Assets, Net	$ 18,351	18,351
CLIA Diagnostic Lab [Member]
Finite-lived intangible asset, useful life	2 years 109 days
Finite-Lived Intangible Assets, Net	$ 609	609
RedPath [Member]
Finite-Lived Intangible Assets, Net	43,011	47,468
Finite-Lived Intangible Assets, Net	37,220	43,492
Finite-Lived Intangible Assets, Accumulated Amortization	$ (6,400)	$ (4,585)

Note 4 - Other Intangible Ass41

Note 4 - Other Intangible Assets - Future Estimated Amortization Expense (Details) $ in Thousands	Sep. 30, 2016USD ($)
2,016	$ 3,771
2,017	4,272
2,018	5,292
2,019	5,292
2,020	$ 5,292

Note 5 - Fair Value Measureme42

Note 5 - Fair Value Measurements - Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Cash [Member] | Reported Value Measurement [Member]
Cash and cash equivalents, fair value disclosure	$ 1,693	$ 7,534
Cash [Member] | Estimate of Fair Value Measurement [Member]
Cash and cash equivalents, fair value disclosure	1,693	7,534
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents, fair value disclosure	1,693	7,534
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents, fair value disclosure
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Reported Value Measurement [Member]
Cash and cash equivalents, fair value disclosure		776
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]
Cash and cash equivalents, fair value disclosure		776
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents, fair value disclosure		776
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents, fair value disclosure	1,693
Reported Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | US Treasury Securities [Member]
Investments, fair value disclosure		1,115
Reported Value Measurement [Member] | Marketable Securities, Money Market Funds [Member]
Investments, fair value disclosure		48
Reported Value Measurement [Member] | Mutual Funds [Member]
Investments, fair value disclosure		58
Reported Value Measurement [Member] | Government Agency Securities [Member]
Investments, fair value disclosure		131
Reported Value Measurement [Member] | Asuragen [Member]
Contingent consideration, deferred payments	3,247	4,628
Reported Value Measurement [Member] | RedPath [Member]
Contingent consideration, deferred payments	14,653	13,921
Reported Value Measurement [Member]
Cash and cash equivalents, fair value disclosure	1,693	8,310
Investments, fair value disclosure		1,352
Contingent consideration, deferred payments	17,900	18,549
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]
Investments, fair value disclosure		1,115
Estimate of Fair Value Measurement [Member] | Marketable Securities, Money Market Funds [Member]
Investments, fair value disclosure		48
Estimate of Fair Value Measurement [Member] | Mutual Funds [Member]
Investments, fair value disclosure		58
Estimate of Fair Value Measurement [Member] | Government Agency Securities [Member]
Investments, fair value disclosure		131
Estimate of Fair Value Measurement [Member] | Asuragen [Member]
Contingent consideration, deferred payments	3,247	4,628
Estimate of Fair Value Measurement [Member] | RedPath [Member]
Contingent consideration, deferred payments	14,653	13,921
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents, fair value disclosure	1,693	8,310
Investments, fair value disclosure		1,352
Contingent consideration, deferred payments	17,900	18,549
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Investments, fair value disclosure		1,115
Fair Value, Inputs, Level 1 [Member] | Marketable Securities, Money Market Funds [Member]
Investments, fair value disclosure		48
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]
Investments, fair value disclosure		58
Fair Value, Inputs, Level 1 [Member] | Government Agency Securities [Member]
Investments, fair value disclosure		131
Fair Value, Inputs, Level 1 [Member] | Asuragen [Member]
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member] | RedPath [Member]
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents, fair value disclosure		8,310
Investments, fair value disclosure		1,352
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Marketable Securities, Money Market Funds [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Government Agency Securities [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Asuragen [Member]
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member] | RedPath [Member]
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents, fair value disclosure
Investments, fair value disclosure
Contingent consideration, deferred payments
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Marketable Securities, Money Market Funds [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Mutual Funds [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Government Agency Securities [Member]
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Asuragen [Member]
Contingent consideration, deferred payments	3,247	4,628
Fair Value, Inputs, Level 3 [Member] | RedPath [Member]
Contingent consideration, deferred payments	14,653	13,921
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents, fair value disclosure
Investments, fair value disclosure
Contingent consideration, deferred payments	$ 17,900	$ 18,549

Note 5 - Fair Value Measureme43

Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) - Contingent Consideration [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Asuragen [Member]
Beginning Balance	$ 4,628
Payments	(450)
Accretion	243
Adjustments to Fair Value	(1,174)
Ending Balance	3,247
RedPath [Member]
Beginning Balance	13,921
Payments
Accretion	732
Adjustments to Fair Value
Ending Balance	14,653
Beginning Balance	18,549
Payments	(450)
Accretion	975
Adjustments to Fair Value	(1,174)
Ending Balance	$ 17,900

Note 6 - Commitments and Cont44

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)

Feb. 28, 2017

Oct. 31, 2016

Oct. 13, 2016

Jul. 31, 2016

May 27, 2016

Jun. 16, 2015

Jun. 03, 2015

Oct. 31, 2014

May 31, 2016

Mar. 31, 2016

Mar. 31, 2016

Sep. 30, 2016

Oct. 31, 2016

Dec. 31, 2015

Former Owners of RedPath [Member] | Subsequent Event [Member]

Loss Contingency Accrual, Payments

$ 170,000

Former Owners of RedPath [Member]

Business Combination, Indemnification Assets, Amount as of Acquisition Date

$ 2,500,000

DOJ [Member] | Subsequent Event [Member]

Loss Contingency Accrual, Payments

$ 85,000

DOJ [Member] | Scenario, Forecast [Member]

Loss Contingency Accrual, Payments

$ 80,000

DOJ [Member]

Loss Contingency, Renegotiated, Amount

$ 250,000

Loss Contingency Accrual, Payments

$ 85,000

Subsequent Event [Member] | Companys Counter-claim Against Prolias [Member]

Litigation Settlement, Amount

$ 500,000

Loss Contingency, Damages Sought, Value

$ (621,236.16)

Loss Contingency, Interest on Settlement

10.00%

Loss Contingency Damages Sought, Value, Attorney Fees

$ 390,769.04

Other Accrued Expenses [Member]

Regulatory Liabilities

$ 700,000

Other Noncurrent Liabilities [Member]

Regulatory Liabilities

1,000,000

Companys Counter-claim Against Prolias [Member]

Loss Contingency, Damages Sought, Value

$ 500,000

Notes Issued

$ 1,000,000

Swann vs. Akorn, Inc, and Interpace Diagnostics Group, Inc. [Member]

Loss Contingency, Damages Sought, Value

$ 300,000

Continuing Operations [Member]

Severance Costs

$ 500,000

2,300,000

Discontinued Operations [Member]

Severance Costs

800,000

Letters of Credit Outstanding, Amount

$ 300,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

500,000

500,000

500,000

Common Stock, Par or Stated Value Per Share

$ 0.01

$ 0.01

$ 0.01

Adjustments to Additional Paid in Capital, Other

$ (6,100,000)

$ (6,800,000)

Stock Issued During Period, Value, Treasury Stock Reissued

$ 6,100,000

$ 6,800,000

Litigation Settlement, Amount

$ 3,000,000

Regulatory Liabilities

$ 1,700,000

Severance Costs

$ 1,100,000

$ 3,100,000

$ 3,700,000

Note 7 - Accrued Expenses and45

Note 7 - Accrued Expenses and Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued royalties	$ 504	$ 111
Self insurance and benefit accruals	272	366
Indemnification liability	875	875
Contingent consideration	209	659
Rent payable	78	127
DOJ settlement	665	250
Accrued professional fees	1,320	775
Taxes payable	691	591
Unclaimed property	544	546
Directors fees and insurance	208	107
All others	1,539	1,554
	$ 6,905	$ 5,961

Note 7 - Accrued Expenses and46

Note 7 - Accrued Expenses and Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Rent payable		$ 52
Uncertain tax positions	3,556	3,425
DOJ settlement (indemnified by RedPath)	1,000	2,500
Other Liabilities Noncurrent	59	201
	$ 4,615	$ 6,178

Note 8 - Stock-based Compensa47

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Oct. 14, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
RSU's and Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.25
RSU's and Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Employee Stock Option [Member] | CEO, CFO, and Certain Employees [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
CEO, CFO, and Certain Employees [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	878,744
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized							2,450,000
Allocated Share-based Compensation Expense			$ 20	$ 300	$ 100	$ 1,000

Note 8 - Stock-based Compensa48

Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Risk-free interest rate		1.02%
Expected life (years)		3 years 182 days
Expected volatility		54.47%
Dividend yield		0.00%

Note 9 - Income Taxes - Income

Note 9 - Income Taxes - Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Provision (benefit) from income tax	$ 173	$ (180)	$ (54)	$ (430)
Effective income tax rate	(2.50%)	2.40%	0.40%	1.90%

Note 10 - Segment Information (

Note 10 - Segment Information (Details Textual)	12 Months Ended
	Dec. 31, 2015
Number of Reportable Segments	1

Note 11 - Discontinued Operat51

Note 11 - Discontinued Operations - Results Included in Loss From Discontinued Operations, Net of Tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue, net		$ 34,119	$ 1,644	$ 104,408
(Loss) income from discontinued operations	(414)	2,576	(1,006)	6,615
Gain on sale of assets			1,326	217
(Loss) income from discontinued operations, before tax	(414)	2,576	320	6,832
Income tax (benefit) expense	(117)	2	219	4
(Loss) income from discontinued operations, net of tax	$ (297)	$ 2,574	$ 101	$ 6,828

Note 11 - Discontinued Operat52

Note 11 - Discontinued Operations - Assets and Liabilities Classified as Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Commercial Services [Member]
Accounts receivable, net		$ 3,296
Unbilled receivable, net		16
Other		2,062
Current assets from discontinued operations		5,374
Property and equipment, net		190
Other
Long-term assets from discontinued operations		190
Total assets		5,564
Accounts payable	947	3,767
Unearned contract revenue		11
Accrued salary and bonus	1,686	3,036
Other, liabilities	2,052	5,092
Current liabilities from discontinued operations	4,685	11,906
Total liabilities	4,685	11,906
Other Discontinued Operations [Member]
Accounts receivable, net
Unbilled receivable, net
Other	150
Current assets from discontinued operations	150
Property and equipment, net
Other		150
Long-term assets from discontinued operations		150
Total assets	150	150
Accounts payable
Unearned contract revenue
Accrued salary and bonus
Other, liabilities	70	358
Current liabilities from discontinued operations	70	358
Total liabilities	70	358
Accounts receivable, net		3,296
Unbilled receivable, net		16
Other	150	2,062
Current assets from discontinued operations	150	5,374
Property and equipment, net		190
Other		150
Long-term assets from discontinued operations		340
Total assets	150	5,714
Accounts payable	947	3,767
Unearned contract revenue		11
Accrued salary and bonus	1,686	3,036
Other, liabilities	2,122	5,450
Current liabilities from discontinued operations	4,755	12,264
Total liabilities	$ 4,755	$ 12,264

Note 12 - Long-term Debt (Detai

Note 12 - Long-term Debt (Details Textual) - USD ($)	Nov. 14, 2016	Dec. 22, 2015	Oct. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015
RedPath Integrated Pathology, Inc [Member] | Notes Payable, Other Payables [Member] | The Note [Member]
Debt Instrument, Face Amount			$ 11,000,000
Debt Instrument, Covenant Term, Net Cash Balance, Amount	$ 400,000
Debt Instrument, Covenant Term, Rolling Net Cash Flow Analysis	91 days
Long-term Debt				$ 9,000,000		$ 9,000,000		$ 10,700,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Business Combination, Consideration Transferred, Liabilities Incurred			$ 7,500,000
Interest Expense, Debt				200,000	$ 200,000	600,000	$ 600,000
Debt Instrument, Unamortized Discount				1,700,000		1,700,000
RedPath Integrated Pathology, Inc [Member] | Loans Payable [Member]
Debt Instrument, Face Amount			20,000,000
Proceeds from Issuance of Debt			$ 19,600,000
RedPath Integrated Pathology, Inc [Member]
Business Combination, Indemnification Assets, Amount as of Acquisition Date				1,500,000		1,500,000
Regulatory Liabilities				1,700,000		1,700,000
Interest Expense, Debt				539,000	$ 884,000	1,601,000	$ 2,616,000
Regulatory Liabilities				$ 1,700,000		$ 1,700,000
Payments for Other Fees		$ 1,600,000

Note 12 - Long-term Debt - Long

Note 12 - Long-term Debt - Long-term Debt Future Principal Payments (Details) $ in Thousands	Sep. 30, 2016USD ($)
2,016	$ 1,334
2,017	4,001
2,018	$ 5,335

Note 13 - Supplemental Cash F55

Note 13 - Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net cash (used in) provided by operating activities of discontinued operations	$ (1,486)	$ 7,466
Net cash (used in) provided by investing activities of discontinued operations